626 related articles for article (PubMed ID: 19856814)
21. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
22. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
23. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
[TBL] [Abstract][Full Text] [Related]
24. Updating practices in an evolving IV iron and anemia environment: practical solutions.
Amerling R; Easom A; Juergensen P
Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
[TBL] [Abstract][Full Text] [Related]
25. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
Charytan C
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
[TBL] [Abstract][Full Text] [Related]
26. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
Katodritou E; Dimopoulos MA; Zervas K; Terpos E
Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
[TBL] [Abstract][Full Text] [Related]
27. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated.
Katodritou E; Zervas K; Terpos E; Brugnara C
Br J Haematol; 2008 Jul; 142(1):3-10. PubMed ID: 18430192
[TBL] [Abstract][Full Text] [Related]
28. Dialysis adequacy and response to erythropoiesis-stimulating agents: what is the evidence base?
Locatelli F; Del Vecchio L; Pozzoni P; Andrulli S
Semin Nephrol; 2006 Jul; 26(4):269-74. PubMed ID: 16949464
[TBL] [Abstract][Full Text] [Related]
29. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Ogawa T; Nitta K
Contrib Nephrol; 2015; 185():76-86. PubMed ID: 26023017
[TBL] [Abstract][Full Text] [Related]
30. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Doss S; Schiller B
Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
[TBL] [Abstract][Full Text] [Related]
31. No associations between prolactin concentrations and response to erythropoiesis-stimulating agents in hemodialysis patients.
Riegersperger M; van Houte M; Födinger M; Wojcik J; Hörl WH; Winkelmayer WC; Sunder-Plassmann G
Am J Nephrol; 2007; 27(4):390-6. PubMed ID: 17587788
[TBL] [Abstract][Full Text] [Related]
32. Anemia management among hemodyalisis patients at the University Hospital in Puerto Rico.
Ocasio HE; Diaz H; Cangiano JL; Báez R; Suárez E
Bol Asoc Med P R; 2014; 106(2):9-12. PubMed ID: 25065044
[TBL] [Abstract][Full Text] [Related]
33. [Additional measures of treatment in patients with renal anemia].
Belavić Z; Kupres V
Acta Med Croatica; 2009 Sep; 63 Suppl 1():62-8. PubMed ID: 20232553
[TBL] [Abstract][Full Text] [Related]
34. Shortened red blood cell lifespan is related to the dose of erythropoiesis-stimulating agents requirement in patients on hemodialysis.
Sato Y; Mizuguchi T; Shigenaga S; Yoshikawa E; Chujo K; Minakuchi J; Kawashima S
Ther Apher Dial; 2012 Dec; 16(6):522-8. PubMed ID: 23190511
[TBL] [Abstract][Full Text] [Related]
35. Iron therapy in chronic kidney disease: current controversies.
Kovesdy CP; Kalantar-Zadeh K
J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
[TBL] [Abstract][Full Text] [Related]
36. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
Schiavetto I; Pedrazzoli P; Basilico V; Siena S
Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
[TBL] [Abstract][Full Text] [Related]
37. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
[TBL] [Abstract][Full Text] [Related]
38. The role of erythropoiesis-stimulating agents in the treatment of anemia.
Fishbane S
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
[TBL] [Abstract][Full Text] [Related]
39. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
40. Hemoglobin level variability: anemia management among variability groups.
Gilbertson DT; Peng Y; Bradbury B; Ebben JP; Collins AJ
Am J Nephrol; 2009; 30(6):491-8. PubMed ID: 19786739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
